Merck & Co., Inc.·4

Jan 29, 6:23 PM ET

Oosthuizen Johannes Jacobus 4

4 · Merck & Co., Inc. · Filed Jan 29, 2025

Insider Transaction Report

Form 4
Period: 2025-01-27
Oosthuizen Johannes Jacobus
EVP, Oncology & Int?l
Transactions
  • Award

    Common Stock

    [F1][F2]
    2025-01-27$97.94/sh+8,664$848,55232,607.474 total
Footnotes (2)
  • [F1]Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024.
  • [F2]Holdings include shares acquired in dividend reinvestment transactions.
Signature
/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen|2025-01-29

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT